Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer

Integrative Cancer Therapies - United States
doi 10.1177/1534735418803755
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Clinical Cancer Research
Cancer ResearchOncology
2016English

Eastern Cooperative Oncology Group Phase II Trial of Lapatinib in Men With Biochemically Relapsed, Androgen Dependent Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2013English

Lenalidomide Modulates IL-8 and Anti-Prostate Antibody Levels in Men With Biochemically Recurrent Prostate Cancer

Prostate
OncologyUrology
2011English

Phytotherapeutic Interventions in the Management of Biochemically Recurrent Prostate Cancer: A Systematic Review of Randomised Trials

BJU International
Urology
2016English

High-Dose Itraconazole as a Noncastrating Therapy for a Patient With Biochemically Recurrent Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2014English

Tailored Postoperative Treatment of Prostate Cancer: Final Results of a Phase I/Ii Trial

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2018English

Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Urology
Urology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy